Open AccessConcise Drug Review: Azacitidine and Decitabine
Author(s) -
Derissen Ellen J.B.,
Beijnen Jos H.,
Schellens Jan H.M.
Publication year - 2013
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2012-0465
Subject(s) - azacitidine , decitabine , medicine , myelodysplastic syndromes , myeloid leukemia , chronic myelomonocytic leukemia , hypomethylating agent , drug , oncology , pharmacology , dna methylation , bone marrow , biochemistry , gene expression , chemistry , gene
The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher‐risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.